

PI3KR2 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP8024b

Specification

PI3KR2 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession <u>000459</u>

PI3KR2 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 5296

Other Names

Phosphatidylinositol 3-kinase regulatory subunit beta, PI3-kinase regulatory subunit beta, PI3K regulatory subunit beta, PtdIns-3-kinase regulatory subunit beta, Phosphatidylinositol 3-kinase 85 kDa regulatory subunit beta, PI3-kinase subunit p85-beta, PtdIns-3-kinase regulatory subunit p85-beta, PIK3R2

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP8024b was selected from the C-term region of human PI3KR2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PI3KR2 Antibody (C-term) Blocking Peptide - Protein Information

Name PIK3R2

Function

Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5- bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Binds to activated (phosphorylated) protein- tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Indirectly regulates autophagy (PubMed:23604317). Promotes nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin- dependent manner during



metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (By similarity).

PI3KR2 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

PI3KR2 Antibody (C-term) Blocking Peptide - Images

PI3KR2 Antibody (C-term) Blocking Peptide - Background

PI3KR2 binds to activated (phosphorylated) protein-tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane.

PI3KR2 Antibody (C-term) Blocking Peptide - References

Janssen, J.W., et al., Oncogene 16(13):1767-1772 (1998). Volinia, S., et al., Oncogene 7(4):789-793 (1992). Carpenter, C.L., et al., J. Biol. Chem. 265(32):19704-19711 (1990).